503A vs. 503B After the Ban: The Only Compounding Pathway That Survives

503B outsourcing is dying. 503A patient-specific compounding lives on. Understanding the difference is now essential for anyone on compounded GLP-1 medication.

The Two Compounding Pathways

Federal law created two distinct pathways for drug compounding after the 2012 NECC meningitis disaster that killed dozens of patients. Understanding both is no longer optional for GLP-1 patients — one pathway is about to close permanently.

503A: Patient-Specific Compounding

Section 503A pharmacies are traditional state-licensed compounding pharmacies and physicians. They compound medications for individual patients based on specific prescriptions. Key characteristics: each prescription is patient-specific (the pharmacist compounds for a named patient with a valid prescription), state-regulated rather than FDA-registered, limited scale (one prescription at a time, not bulk batches), and exempt from FDA manufacturing requirements in exchange for the patient-specific limitation.

503B: Outsourcing Facilities

Section 503B outsourcing facilities are FDA-registered operations that compound drugs in larger quantities without patient-specific prescriptions. They can produce batch quantities for distribution to healthcare providers and facilities. The 503B pathway is what enabled the telehealth GLP-1 industry — platforms like Hims, Ro, LifeMD, and dozens of others sourced compounded semaglutide and tirzepatide from 503B facilities at scale.

What Changes and What Doesn't

When the 503B exclusion takes effect, outsourcing facilities lose the ability to compound semaglutide, tirzepatide, and liraglutide from bulk ingredients. This eliminates the supply chain that most large telehealth platforms depend on.

What doesn't change: 503A pharmacies can still compound these medications for individual patients with valid prescriptions from licensed prescribers. Your doctor or nurse practitioner can still write a prescription for compounded semaglutide, and a 503A pharmacy can still fill it.

The Practical Differences for Patients

503A compounding after the ban will look different from the 503B-powered telehealth experience most patients know. Scale is smaller — 503A pharmacies compound one prescription at a time, not batches of thousands. This means longer wait times (days rather than next-day shipping) and potentially higher per-unit costs (no bulk pricing efficiencies).

Geographic access varies. Not every state has the same density of compounding pharmacies, and state regulations differ on what 503A pharmacies can compound and under what conditions. Some states have more permissive frameworks; others restrict compounding more tightly.

The prescriber relationship becomes more important. In the 503B model, telehealth platforms handled both the prescription and the pharmacy routing. In a 503A world, your prescriber needs an established relationship with a compounding pharmacy — or you need to find one yourself.

How to Find a 503A Pharmacy

The Professional Compounding Centers of America (PCCA) maintains a pharmacy locator. Your state board of pharmacy has a list of licensed compounding pharmacies. Ask your prescriber directly — physicians who regularly prescribe compounded medications typically have established 503A pharmacy relationships.

When evaluating a 503A pharmacy, look for PCAB (Pharmacy Compounding Accreditation Board) accreditation, active state licensure in good standing, experience with injectable sterile compounding (critical for GLP-1 injectables), and clear pricing before you commit.